Kaléo announced today that they will reintroduce AUVI-Q (epinephrine injection, USP) to the U.S. market in the first half of 2017.
AUVI-Q is a prescription medicine used to treat life-threatening allergic reactions including anaphylaxis in people at risk of serious allergic reactions. With voice prompted, step-by-step delivery instructions and a needle that automatically retracts following administration, AUVI-Q is indicated for self and caregiver administration in emergency situations.
AUVI-Q contains epinephrine which acts on both alpha and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.
Regarding pricing, Kaléo President and CEO, Spencer Williamson said, “We believe that the patient should be able to obtain the product without insurance barriers or being subjected to a high out-of-pocket cost. As we prepare to make AUVI-Q available once again in the United States, our priority is to return AUVI-Q to the market as an epinephrine auto-injector alternative that all patients can afford.”
In a press release, Kaléo indicated that each AUVI-Q device goes through 100 automated quality checks, ‘ensuring a streamlined and consistent production process.’
Healthcare practitioners and members of the public may receive the lasted updates on AUVI-Q’s availability by registering online at www.auvi-q.com.